Your Health: Simple steps to a better you.

Sickle Cell Anemia is a hereditary blood disorder that affects millions of people globally. The traditional treatments for this condition often come with limitations and side effects, prompting researchers to explore innovative solutions. One such groundbreaking technology gaining attention is CRISPR Cas9.  In this article, we delve into the potential of CRISPR Cas9 in revolutionizing the treatment landscape for Sickle Cell Anemia. Understanding Sickle Cell Anemia Genetic Basis Sickle Cell Anemia is caused by a mutation in the HBB gene, leading to the production of abnormal hemoglobin known as hemoglobin S (HbS). Individuals with two copies of the mutated gene (HbS/HbS) develop Sickle Cell Anemia, while those with one normal and one mutated gene (HbA/HbS) are carriers but generally do not exhibit symptoms. Hemoglobin S tends to polymerize under conditions of low oxygen, causing red blood cells to deform and adopt a sickle shape. These sickle cells are less flexible and more prone to ge